Classic Warrior
2 weeks ago
Yea. It's my biggest loss, but I my optimism is all but gone. Mistakes were made for sure, but hopefully, the Canadian Department of Defense will see something in the drug and save the day. I still wonder what Derrick has been doing on the psychedelic side and the weed angle. What about those patented strips? I'd say we have about a 3% chance of recovery, but I have been wrong before and hope I am again.
ps. Good luck, but profits elsewhere may be more realistic at this time.
Ecomike
2 months ago
Dig back a year or more back and I said here that $RVVTF could and might go after this application, because Bucci had this potential based on what was already known, and what do you know, there it is.
Great post:
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
July 02, 2024 13:58 ET
TORONTO, July 02, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (โReviveโ or the โCompanyโ) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today an update on the research study evaluating Bucillamine as a potential treatment for nerve agent exposure, in partnership with Defence R&D Canada โ Suffield Research Centre (โDRDCโ), an agency of the Canadian Department of National Defence. The DRDC is investigating pharmacological compounds, including Bucillamine, that can mitigate nerve agent induced brain injury. Control studies have been initiated and the DRDC expects to evaluate the data this month. Treatment studies will follow after the conclusion of the control group evaluation. The research study is expected to be completed in August 2024.
Nerve agents are chemicals that affect the nervous system. Nerve agents are highly toxic regardless of the route of exposure. The main chemical nerve agents that are man-made and manufactured for use in chemical warfare are sarin, soman, tabun and VX. These nerve agents are known to be present in military stockpiles. Exposure to nerve agents can occur due to chemical warfare or accidental release from a military storage facility. Exposure to nerve agents can cause tightness of the chest, excessive salivation, abdominal cramps, diarrhea, blurred vision, tremors, and death.
Recent studies have shown that antioxidant compounds such as n-acetylcysteine (โNACโ) could be beneficial in limiting seizure activity and improving the anticonvulsant efficacy of GABA-mediating drugs such as diazepam.
Bucillamine is a significantly more effective antioxidant than NAC and has the potential to provide increased efficacy against seizure activity while limiting the anticoagulant and bleeding event liability observed with NAC. The overall objective of the research project is to investigate pharmacological means for neuroprotection of GABA(A) receptors, which are required for the effectiveness of currently fielded anticonvulsant therapies. Bucillamine and NAC will be evaluated to determine the effect on GABA(A) receptor endocytosis and the effect on diazepam effectiveness in terminating seizures. Any additional antioxidant effects on seizure activity and survival will also be assessed.
The results from this research study, if promising, will determine further studies to facilitate FDA and Health Canada approvals for the use of Bucillamine in nerve agents or organophosphate pesticide poisoning. Also, the Company may explore the potential of Bucillamine for traumatic brain injury caused by concussive or explosive forces.
https://www.globenewswire.com/news-release/2024/07/02/2907735/0/en/Revive-Therapeutics-Provides-Update-on-Research-Study-Evaluating-Bucillamine-for-Nerve-Agent-Exposure.html
ReikoBlack
3 months ago
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
July 02, 2024 13:58 ET
TORONTO, July 02, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (โReviveโ or the โCompanyโ) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today an update on the research study evaluating Bucillamine as a potential treatment for nerve agent exposure, in partnership with Defence R&D Canada โ Suffield Research Centre (โDRDCโ), an agency of the Canadian Department of National Defence. The DRDC is investigating pharmacological compounds, including Bucillamine, that can mitigate nerve agent induced brain injury. Control studies have been initiated and the DRDC expects to evaluate the data this month. Treatment studies will follow after the conclusion of the control group evaluation. The research study is expected to be completed in August 2024.
Nerve agents are chemicals that affect the nervous system. Nerve agents are highly toxic regardless of the route of exposure. The main chemical nerve agents that are man-made and manufactured for use in chemical warfare are sarin, soman, tabun and VX. These nerve agents are known to be present in military stockpiles. Exposure to nerve agents can occur due to chemical warfare or accidental release from a military storage facility. Exposure to nerve agents can cause tightness of the chest, excessive salivation, abdominal cramps, diarrhea, blurred vision, tremors, and death.
Recent studies have shown that antioxidant compounds such as n-acetylcysteine (โNACโ) could be beneficial in limiting seizure activity and improving the anticonvulsant efficacy of GABA-mediating drugs such as diazepam.
Bucillamine is a significantly more effective antioxidant than NAC and has the potential to provide increased efficacy against seizure activity while limiting the anticoagulant and bleeding event liability observed with NAC. The overall objective of the research project is to investigate pharmacological means for neuroprotection of GABA(A) receptors, which are required for the effectiveness of currently fielded anticonvulsant therapies. Bucillamine and NAC will be evaluated to determine the effect on GABA(A) receptor endocytosis and the effect on diazepam effectiveness in terminating seizures. Any additional antioxidant effects on seizure activity and survival will also be assessed.
The results from this research study, if promising, will determine further studies to facilitate FDA and Health Canada approvals for the use of Bucillamine in nerve agents or organophosphate pesticide poisoning. Also, the Company may explore the potential of Bucillamine for traumatic brain injury caused by concussive or explosive forces.
https://www.globenewswire.com/news-release/2024/07/02/2907735/0/en/Revive-Therapeutics-Provides-Update-on-Research-Study-Evaluating-Bucillamine-for-Nerve-Agent-Exposure.html